search
Back to results

Critical Congenital Heart Defect (CHD) Outcomes in Children

Primary Purpose

Congenital Heart Disease

Status
Terminated
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
Emory University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Congenital Heart Disease focused on measuring pediatric, congenital heart disease

Eligibility Criteria

1 Day - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Critical congenital heart disease Signed informed consent Exclusion Criteria: Not diagnosed with critical congenital heart disease No signed informed consent

Sites / Locations

  • Children's Healthcare of Atlanta

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 13, 2005
Last Updated
February 11, 2014
Sponsor
Emory University
search

1. Study Identification

Unique Protocol Identification Number
NCT00208689
Brief Title
Critical Congenital Heart Defect (CHD) Outcomes in Children
Official Title
A Review of the Diagnosis, Treatment and Outcomes of Children With Critical Congenital Heart Defects
Study Type
Observational

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Terminated
Study Start Date
January 2004 (undefined)
Primary Completion Date
May 2006 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University

4. Oversight

5. Study Description

Brief Summary
Congenital heart disease in infants and children often challenges healthcare providers both in regards to diagnosis and in the management of these conditions. The field becomes more complicated as one examines the myriad of defects that present and the complex care that is required. Over the last 20-25 years, the remarkable advances in the medical and surgical management of the most complex lesions have decreased neonatal mortality, such that many more survive the neonatal period. Therefore, new challenges regarding the continued care of this patient cohort of high-risk infants and children exist. In order to continue the improvement of treatment(s) offered to these patients, continuous review and analysis of the current standard of care is needed. In this study, the investigators will collect information related to the current surgical and medical therapies offered to patients enrolled in the High Risk Congenital Heart Program at Children's Healthcare of Atlanta. All of the procedure and visit information will be a part of the child's standard of care. This information will be placed in a database. The investigators hope to learn more about the short-term and long-term effects of current therapies and procedures.
Detailed Description
Patients, age newborn to 21 years, followed in the High Risk Congenital Heart Defect Clinic at Children's Healthcare of Atlanta at Egleston will be asked to participate in this trial. The term "high risk" is assigned to a patient with the following diagnoses or medical problems: critical aortic stenosis, truncus arteriosus (with or without interrupted aortic arch), patients with complex single ventricle physiology (such as hypoplastic left heart syndrome, unbalanced AV canal, tricuspid atresia, transposition of the great vessels with ventricular septal defect and pulmonary stenosis, mitral atresia, pulmonary atresia with intact ventricular septum), left ventricular outflow tract obstruction requiring Konno procedure, transposition of the great vessels (with or without ventricular septal defect), pulmonary atresia with ventricular septal defect, interrupted aortic arch (with or without ventricular septal defect), anatomy requiring "double switch" procedure, aortic arch abnormality requiring transverse arch graft, total anomalous pulmonary venous return, anatomy requiring any of the following procedures: Damas-Kaye-Stansel procedure, ventricular septal defect enlargement, or resection of subpulmonic stenosis during arterial switch procedure, atrial septectomy, neonatal repositioning of the tricuspid valve for Ebstein anomaly, Ross procedure in infancy; mitral stenosis with mitral valve replacement in infancy, and any other cardiac abnormality requiring surgical repair in infancy with residual hemodynamically significant lesions. In addition, patients with infantile Marfan syndrome, or kawasaki disease with coronary artery aneurysm will also be included. Informed consent will be obtained from the parent or legally authorized representative for all study participants. An Assent, either verbal or written, will also be obtained if the child is over the age of six (6). A sequential and unique subject number (i.e. NES.001, NES.002) will be assigned by the investigator or designee to each qualified subject after informed consent has been obtained. Once a subject number is assigned, it will not be used again by the investigator. Subjects who are asked to participate but refuse participation in the study will not be assigned a study number. Investigational Plan: A single-center, retrospective registry design will be utilized. After consent, the following data will be collected from each study participant's chart each time he or she attends clinic: Name Contact information (or confirm contact information) Names of other care providers Primary Diagnosis Secondary Diagnoses Age at time of visit Vital signs including blood pressure, heart rate, respirations, pulse oximetry Weight at time of visit If applicable, echocardiography data including m-mode, tissue doppler and color flow Doppler History and Physical including surgical history Medications Nutritional Status Growth Parameters If applicable, most recent standard of care laboratories If applicable, MRI results EKG findings All procedures are standard of care. The collection of data for this registry will not effect the care provided to each patient. The individual physician has the right to diagnose and treat each patient according to standard of care procedures and his/her own medical judgement. Participation in this registry will last as long as the patient is being followed in the high risk clinic at Children's Healthcare of Atlanta.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Heart Disease
Keywords
pediatric, congenital heart disease

7. Study Design

Enrollment
150 (false)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Critical congenital heart disease Signed informed consent Exclusion Criteria: Not diagnosed with critical congenital heart disease No signed informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martha Clabby, MD
Organizational Affiliation
Emory University and Children's Healthcare of Atlanta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Healthcare of Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Critical Congenital Heart Defect (CHD) Outcomes in Children

We'll reach out to this number within 24 hrs